Fact-checked by Grok 2 weeks ago

Victor Chang Cardiac Research Institute

The Victor Chang Cardiac Research Institute (VCCRI) is an independent, not-for-profit facility in focused on advancing the understanding, prevention, diagnosis, and treatment of , 's second leading , causing around 43,800 fatalities annually (as of 2024). Established in 1994 in honor of the renowned heart transplant surgeon Dr. AC, who was tragically murdered in 1991, the institute was officially opened in 1996 by , at its headquarters in Darlinghurst, . With over 230 scientists, doctors, and staff operating across 26 laboratories in locations including , , , and , the VCCRI conducts innovative, collaborative research to translate scientific breakthroughs into clinical applications that save lives and reduce the approximately $17 billion annual healthcare burden of in (as of 2023-24). Under the leadership of Director and CEO Professor Jason Kovacic, who assumed the role in 2020, the institute emphasizes interdisciplinary approaches, partnering with institutions such as the , the , and the Harry Perkins Institute of Medical Research (2025 collaboration) to expand its national footprint. Its mission is to prevent "heartbreak" by solving complex cardiovascular challenges, from genetic factors to organ preservation techniques, fostering a legacy of excellence that began with just two scientists at inception. The VCCRI has achieved several groundbreaking discoveries that underscore its global impact in heart research. In 2014, researchers developed the "Heart-in-a-Box" technology, a portable device using a unique preservation solution that enables transplantation of donor hearts stopped for up to 20 minutes and extends transport time to 14 hours, enabling the first transplant of a revitalized heart and potentially saving 30% more patients by expanding the donor pool. More recently, in 2024, the institute identified a key genetic driver (PHACTR1) of fibromuscular dysplasia—a condition affecting up to 5% of women—and created the world's first gene mutation test for assessing sudden cardiac arrest risk, paving the way for personalized preventive therapies. Other milestones include the 2022 identification of mechanisms behind cardiac hypertrophy and the ranking of 162 genes associated with heart attacks, highlighting the institute's role in driving forward treatments for one of the world's leading killers, responsible for 19.2 million deaths globally each year (as of 2023).

History

Founding and Early Development

The Victor Chang Cardiac Research Institute was established to honor Dr. Victor Chang AC (1936–1991), a pioneering Australian cardiac surgeon renowned for his advancements in heart transplantation and the development of artificial heart valves. Born in China and educated in Australia and the United Kingdom, Chang led Australia's first successful heart transplant in 1984 at St Vincent's Hospital in Sydney and established the National Heart Transplant Program there in 1984, performing over 200 such procedures during his career. His work extended to creating low-cost St Vincent's Heart Valves for use in Asia and the Pacific, and he initiated research on an artificial heart before his tragic murder in 1991. The institute was officially launched on 14 February 1994 by Australian Prime Minister at a modest site in , , as a tribute to Chang's legacy in advancing cardiovascular medicine. Initial patronage was provided by media magnate AC, who donated $3 million to support the startup phase, complemented by government grants from the Australian federal and governments, as well as private contributions from philanthropists and the community. These funds enabled the foundational setup, emphasizing the prevention, diagnosis, and treatment of heart and vascular diseases through dedicated research. Operations commenced modestly in temporary premises hosted by the nearby Garvan Institute of Medical Research, with the official opening of these facilities occurring on 1 November 1996 by , who toured the laboratories and highlighted the institute's potential to combat heart disease globally. At launch, the institute employed just two scientists, focusing on building basic infrastructure for cardiac research, including laboratory setups and initial recruitment of experts in and to lay the groundwork for independent investigations. This early phase prioritized establishing a collaborative environment within the Garvan's , allowing the nascent team to conduct foundational studies on heart muscle function and genetic factors in cardiovascular conditions.

Expansion and Key Milestones

Since its establishment, the Victor Chang Cardiac Research Institute has experienced significant growth, expanding from just two scientists in 1994 to over 230 staff members across 26 laboratories as of 2025. This expansion reflects the institute's increasing capacity to conduct cutting-edge cardiovascular research nationwide, supported by strategic infrastructure investments and partnerships. A pivotal occurred in with the completion and official opening of the institute's main building in , , by then-Crown Princess of , providing state-of-the-art facilities for research activities. In the same year, the institute formalized its affiliation with through an agreement that enhanced integration and resource sharing. Further institutional development came in 2019 with the establishment of the Victor Chang Innovation Centre, funded in part by a $3.75 million donation from the Packer Family Foundation, to facilitate and commercialization of research discoveries. National expansion accelerated in the 2020s, beginning with the opening of a research hub in in March 2022 through a strategic partnership with the , aimed at boosting heart disease research in the region. This was followed in 2023 by the launch of a cardiovascular research hub in in collaboration with St Vincent's Institute of Medical Research, and integration into the precinct via a partnership with the Ingham Institute, UNSW Sydney, and the South Western Sydney Local Health District, establishing a new Chair in Cardiovascular Research. In June 2025, the institute announced a collaboration with the Harry Perkins Institute of Medical Research to advance heart outcomes research, further strengthening its national presence. Funding has been instrumental in sustaining this growth, with consistent increases in grants from the National Health and Medical Research Council (NHMRC), including four Ideas Grants awarded in 2023 and additional multimillion-dollar awards in 2024 and 2025 for projects on cardiac function and disease prevention. Major philanthropic support includes grants from the in 2024, funding key initiatives in cardiovascular health.

Research Focus

Core Research Programs

The Victor Chang Cardiac Research Institute organizes its cardiovascular research across 26 specialized laboratories, grouped into core programs that address fundamental mechanisms of heart disease, from molecular processes to clinical applications. These programs encompass over 250 , doctors, and staff and emphasize translational approaches to prevention, diagnosis, and treatment. The Molecular Cardiology and program focuses on ion channels and heart rhythm disorders, exploring the electrical properties of cardiac cells to understand arrhythmias and develop targeted therapies. In the Developmental and Stem Cell Biology program, researchers investigate embryonic and regenerative therapies, aiming to uncover genetic and environmental factors in congenital heart defects while advancing -based repair strategies. The Cardiac Physiology and Transplantation program examines organ rejection and transplant , studying immune responses to improve outcomes in and related procedures. Building on stem cell expertise, the Regenerative Medicine and Stem Cells initiative utilizes (iPSC)-derived cardiomyocytes for drug testing and modeling cardiac diseases . The Vascular Biology program delves into blood clotting mechanisms and , identifying pathways to prevent vascular complications in cardiovascular conditions. Within , efforts target genetic variants associated with , employing genomic sequencing to link mutations to disease progression. The Structural and Computational Biology program applies protein modeling for , simulating molecular interactions to accelerate therapeutic development. Interdisciplinary approaches integrate (AI) for analysis and for population-level studies, enhancing diagnostic precision and identifying risk patterns through bioinformatics. As of 2025, ongoing projects include updates to the (SCAD) research program, which leads national efforts to characterize this condition's causes and management, and investigations into risks among elite athletes, revealing elevated prevalence in former rowers.

Major Discoveries and Achievements

The Victor Chang Cardiac Research Institute has made significant contributions to cardiovascular science through landmark genetic discoveries, including the maintenance of the CHDgene database, which catalogs mutations like those in NOTCH1 associated with aortic valve disease and congenital heart defects such as and . This resource has facilitated global research into hereditary cardiac conditions since the early 2000s, aiding in the identification of genes linked to congenital heart disease, with the database cataloging 171 high-confidence genes. Institute researchers have advanced therapies for (HCM), including preclinical studies on peptide interventions targeting calcium channels to prevent and reverse heart muscle thickening. Recent achievements include a 2025 international study revealing how lifestyle factors interact with genetic predispositions in familial (), analyzing data from thousands of patients across multiple cohorts to show that modifiable risks like and exercise could delay onset by up to 10 years in at-risk individuals. That same year, funded research illuminated menopause's role in elevating women's heart disease risk, particularly through decline contributing to aortic aneurysms and vascular stiffness, with grants enabling mechanistic studies to inform gender-specific prevention strategies. These findings underscore the institute's emphasis on gene-environment interactions in preventing and sudden cardiac death. The institute's impact is evidenced by substantial funding and scholarly output, including over 3,000 publications since its founding, with hundreds in high-impact journals such as , Circulation, and the European Heart Journal. In 2025, it secured more than $1 million from the Australian Research Discovery Projects for investigations into mitochondrial energy production in cardiac cells, alongside $2.8 million from the and Medical Research Council for optimizing ion channel function in arrhythmias. In late 2024, the institute was awarded four NHMRC Ideas Grants totaling around $5 million for projects commencing in 2025, focusing on treatments for and , aortic aneurysm understanding, and other cardiovascular challenges. Additional Heart Foundation and NSW Health grants totaling hundreds of thousands supported women's cardiovascular research and therapies. Translational successes include patents for cardiac regeneration methods, such as US Patent 10,017,574, which promotes heart repair through neuregulin and ErbB-2 signaling to stimulate cardiomyocyte proliferation and reduce damage post-infarction. The institute's collaborations have advanced clinical applications, notably contributing to the BiVACOR total artificial heart's development and its first Australian implantation in late 2024 at , enabling a patient to survive 100 days bridged to transplant with improved over traditional devices, with success announced in 2025. Earlier innovations, like the 2014 Heart-in-a-Box system, have increased heart transplant viability by 30% by maintaining organ function during transport, now adopted in clinical protocols worldwide.

Facilities and Locations

Main Campus in Sydney

The main campus of the Victor Chang Cardiac Research Institute is situated at the Lowy Packer Building, 405 Liverpool Street, , Sydney, NSW 2010, within the St Vincent’s Sydney Health Innovation Precinct. This location positions the institute at the heart of a collaborative medical ecosystem, facilitating proximity to clinical and research partners focused on advancing health outcomes. The centerpiece of the campus is the ten-storey Lowy Packer Building, officially opened in by Crown Princess Mary of , which serves as the institute's headquarters for cutting-edge cardiovascular research. The building accommodates 26 specialized laboratories equipped with state-of-the-art infrastructure, including advanced imaging suites for high-resolution MRI assessment of cardiac function, dedicated culturing facilities supporting human (iPSC) reprogramming and modeling, and a bioinformatics core offering customized workflows to support genomic and proteomic studies. Complementing these are amenities such as the Innovation Centre, which promotes the commercialization of research discoveries by providing access to high-throughput technologies and expert support for translational applications in areas like cardiovascular, neurological, and metabolic disorders; and the BioCORE animal research facility, established in to house up to 7,400 cages for preclinical studies while adhering strictly to Australian and standards under the oversight of an Animal Ethics Committee. The campus also integrates seamlessly with St Vincent's Hospital, enabling direct pathways for clinical trials and the rapid translation of laboratory findings into patient care. With a capacity to house over 230 scientists, doctors, and support staff, the facility fosters a collaborative for multidisciplinary . Sustainability enhancements, including energy-efficient upgrades implemented around 2020, have contributed to significant reductions in the building's gas and consumption, aligning with broader goals in medical .

National Hubs and Collaborations

The Victor Chang Cardiac Research Institute has expanded its operations beyond its headquarters through strategic national hubs, enabling broader access to diverse environments and patient populations across . These initiatives foster decentralized cardiovascular while leveraging local expertise and infrastructure. In , the institute established the Heart, Exercise and Research Trials (HEART) Laboratory in in 2023, in partnership with St Vincent's Institute of Medical Research. This hub focuses on , sports , and pulmonary vascular to improve diagnostics and prevention of conditions like sudden . It collaborates with local institutions, including shared efforts with the Heart and Diabetes Institute on projects such as heart attack mechanisms. Affiliated with the through its clinical networks, the lab enhances translational studies in a region with high cardiovascular burden. The hub, launched in 2022 through a strategic partnership with the in , addresses heart disease prevalence in remote and underserved areas. It emphasizes cardiovascular research tailored to health, where Aboriginal and Torres Strait Islander peoples face a 50% higher risk of fatal heart attacks compared to non- populations. In 2025, the hub extended its capabilities via a collaboration with the Harry Perkins Institute of Medical Research, incorporating to advance precision medicine for heart conditions. Supported by industry partners like and Woodside, this initiative includes dedicated labs for clinical trials and data analysis. In 2023, the institute integrated with the Precinct through a partnership with the Ingham Institute for Applied , backed by the South Western Sydney Local Health District and UNSW Sydney. This collaboration targets studies in a diverse area serving over one million residents, including 40% born overseas and significant and communities facing socioeconomic challenges. It provides access to large patient cohorts for epidemiological research on cardiovascular disparities, with 1,500 annual CVD deaths in the region, and leverages shared infrastructure to accelerate community-based interventions. Broader national and international collaborations amplify the institute's impact. Key affiliations include UNSW Sydney for faculty appointments and training programs, and the Garvan Institute of Medical Research within the St Vincent’s Sydney Health Innovation Precinct for integrated and clinical studies. Internationally, the institute maintains ties with the , particularly in cardiovascular research outputs and precision medicine initiatives.

Governance and Organization

Board of Directors

The of the Victor Chang Cardiac Research Institute provides high-level governance, overseeing the organization's strategic direction, , and major initiatives to advance cardiovascular research. As of 2025, the board is chaired by Matthew Grounds AM, a prominent leader and co-executive chair of Barrenjoey Capital Partners, who was appointed in 2013 following his extensive experience in . Key members include Deputy Chairman David Craig, a philanthropist and former Chief Financial Officer of the Commonwealth Bank of Australia, who brings expertise in finance and fundraising, and Professor Jason Kovacic, serving ex officio as the Institute's Director and CEO, representing medical and scientific leadership. The board emphasizes diverse expertise across medicine, business, finance, and law, with recent appointments including Dr. Philip Lowe, former Governor of the Reserve Bank of Australia (June 2025), and Ms. Christine Fleer (July 2024), a partner at Arnold Bloch Leibler law firm, enhancing legal and economic perspectives. The board's primary roles encompass , financial oversight, and to sustain research efforts, including the approval of significant expansions such as the 2022 establishment of the Western Australia research hub in partnership with the . Notable contributions include securing multi-million-dollar philanthropic donations to fund core programs and guiding the development of the Institute's 2022–2030 Strategic Plan, which prioritizes research translation into clinical therapies for heart disease. Tenure typically involves multi-year terms to ensure continuity, with appointments selected for alignment with the Institute's mission of innovative cardiovascular discovery.

Executive Leadership

The executive leadership of the Victor Chang Cardiac Research Institute is headed by Professor Jason Kovacic, who serves as Director and CEO since his appointment in March 2020. A cardiologist and specializing in vascular biology, Kovacic oversees more than 230 staff members, manages the institute's operational budget, and directs international collaborations aimed at advancing cardiovascular research. Prior to his current role, he held senior positions at in , where he led cardiovascular research initiatives, and served as a professor at the (UNSW Sydney). Supporting Kovacic are several deputy directors responsible for key operational and research areas. Professor Sally Dunwoodie acts as Deputy Director and Head of the (formerly known as the ), with a focus on and congenital heart defects; her research has notably identified niacin's role in preventing certain birth defects through studies on embryonic development. Professor Jamie Vandenberg serves as Co-Deputy Director and Head of the , specializing in cardiac channels and to address arrhythmias and sudden cardiac death. Suzie Blinman was appointed Deputy CEO in October 2025, focusing on operational leadership including administration and strategic implementation. The executive team collectively implements the institute's strategic plans, leads funding bids such as the successful 2025 Australian Research Council (ARC) Discovery Projects that awarded over $1 million to institute researchers for studies on biological energy production and lipid roles in ion channels, and fosters interdisciplinary teams across divisions. These efforts occur under the oversight of the , ensuring alignment with broader objectives.

Notable Contributors

Prominent Researchers

Professor Nigel Turner heads the Cellular Laboratory at the Victor Chang Cardiac Research Institute, where his research centers on mitochondrial function and cellular in the of cardiometabolic diseases and cancer. His work investigates how metabolic changes contribute to disease progression, with a particular emphasis on oncogenic signaling in to inform novel therapeutic strategies. Funded by organizations including the National Health and Medical Research Council and Cancer Council NSW, Turner's studies on cellular energy pathways have produced over 170 publications and aim to bridge metabolic insights for improved treatments in heart-related conditions. Professor Diane Fatkin leads the Inherited Heart Diseases Laboratory, specializing in the of cardiomyopathies and . Her team has advanced by identifying genetic variants causing (), enabling targeted interventions that restore heart function in affected families. In a 2025 study, Fatkin and collaborators analyzed factors influencing the onset of titin-related familial , revealing how lifestyle modifications could delay disease progression by decades and reduce risks of and sudden . Among group leaders, Associate Professor Eleni Giannoulatou directs the Computational Genomics Laboratory and spearheads genetic analyses for (SCAD), a key focus of the institute's vascular research. Her contributions include leading genome-wide association studies that identified multiple genetic loci associated with SCAD risk, enhancing understanding of its mechanisms in women and informing preventive strategies. Through the VCCRI Arteriopathies and SCAD Cohort (VASC), Giannoulatou's work has supported over 14 international publications on SCAD since 2017. The institute fosters diversity in its research community by incorporating early-career talents through initiatives like the Young Appeals Committee, with 2024 appointments including Ninette Khouri, Jack Freeman, and Rebecca LeBherz to support fundraising and engagement efforts. This approach ensures broader perspectives in advancing cardiac research programs.

Historical Figures and Patrons

Dr. Victor Chang AC (1936–1991) was a pioneering Chinese-Australian cardiac surgeon whose groundbreaking work in heart transplantation and valve innovation profoundly shaped the Victor Chang Cardiac Research Institute's foundational focus. Born in Shanghai and educated at the University of Sydney, Chang performed 266 heart transplants and 22 heart-lung transplants at St Vincent's Hospital in Sydney by 1991, achieving a 92% one-year survival rate and 85% five-year survival rate—outcomes that established him as a leader in modern cardiac surgery. He developed the St Vincent's Heart Valve in the late 1980s, a low-cost artificial prosthesis that made advanced treatments accessible in Asia and the Pacific, saving hundreds of lives by addressing barriers to care in resource-limited regions. Additionally, Chang pioneered Australia's first successful pediatric heart transplant in 1984 on 14-year-old Fiona Coote and advanced research toward a fully implantable artificial heart. As an advocate for equitable medical access, particularly for Asian-Australians, he facilitated staff exchanges with Southeast Asian institutions and promoted medical diplomacy between Australia and China, earning appointment to the Australia-China Council in 1982 and the Companion of the Order of Australia in 1986 for these efforts. His tragic murder on 4 July 1991 during a failed extortion attempt in Sydney galvanized public and governmental support, leading directly to the institute's creation in 1994 to realize his vision of research-driven solutions for heart disease, with an emphasis on transplantation advancements and reducing disparities in cardiac care. Kerry Packer AC (1937–2005), the influential Australian media proprietor, served as the institute's founding patron from 1994 until his death in 2005, providing pivotal early financial and promotional support rooted in his personal experiences with cardiac health. In 1990, had treated Packer following a life-threatening heart attack, forging a deep bond that inspired Packer's commitment to cardiac research; he donated $3 million in 1994, which funded the institute's initial laboratory setups in a modest red-brick building in , . Packer's high-profile patronage amplified the institute's visibility among Australia's elite, drawing additional resources and enabling the recruitment of early researchers to pursue Chang's goals in heart repair and equity. His contributions were instrumental in transforming the nascent organization from a two-person operation into a viable research hub dedicated to breakthroughs in transplantation and preventive care. The Chang family, led by his widow Ann Chang, provided essential endowment support and advocacy in the institute's formative years, ensuring the perpetuation of Victor's legacy through targeted philanthropy that bolstered administrative and research infrastructure. Complementing these efforts, then-Prime Minister officially launched the institute on 14 February 1994 and committed $3 million in federal funding, matching Packer's donation to deliver the $6 million startup capital needed for operational launch. Together, these early backers enabled the establishment of core programs in transplant innovation and equitable access, directly influencing the institute's emphasis on high-impact cardiac research that has since expanded donor heart viability and addressed inequities.

References

  1. [1]
    Victor Chang Cardiac Research Institute | About Us
    ### Summary of Victor Chang Cardiac Research Institute
  2. [2]
    Professor Jason Kovacic | Victor Chang Cardiac Research Institute
    Jason Kovacic is the Director and CEO of the Victor Chang Cardiac Research Institute, Chair and Professor of Medicine at UNSW Sydney, and Adjunct Professor at ...
  3. [3]
    Victor Chang Cardiac Research Institute and UWA join forces to ...
    Mar 30, 2022 · Professor Jason Kovacic, Executive Director of the Victor Chang Cardiac Research Institute, said the affiliation was the culmination of a ...
  4. [4]
    Victor Chang Cardiac Research Institute | History of Major Discoveries
    ### Major Discoveries and Achievements at Victor Chang Cardiac Research Institute
  5. [5]
    Victor Chang Cardiac Research Institute: Home of Heart Research
    With more than 200 scientists and 26 laboratories across Australia, the Victor Chang Cardiac Research Institute is the Australian headquarters for world-class ...About UsOur ScientistsContact usCareersDonate today
  6. [6]
    Victor Peter Chang - Australian Dictionary of Biography
    In 1984 Chang established the Victor Chang Foundation. The same year, the National Heart Transplant Program was awarded to St Vincent's Hospital under his ...
  7. [7]
    30 Years of the Home of… | Victor Chang Cardiac Research Institute
    Feb 14, 2024 · The Victor Chang Cardiac Research Institute celebrates 30 years as a world-renowned heart research institute with over 230 staff working across 23 labs.
  8. [8]
    [PDF] Victor Chang Cardiac Research Institute - Imgix
    Now all Bob needed was funding. Lots of it. In the early 1990s when Kerry Packer was asked for $3million to help establish the Institute he famously replied ...
  9. [9]
    Princess Diana & Our… | Victor Chang Cardiac Research Institute
    In 1996, Diana, Princess of Wales officially opened the Victor Chang Cardiac Research Institute's temporary premises in Darlinghurst. During her time in ...
  10. [10]
    10 Year Building Anniversary | Victor Chang Cardiac Research ...
    Sep 5, 2018 · When the Victor Chang Cardiac Research Institute was established in 1994, it started with just two scientists. Today there are 300 staff and ...
  11. [11]
    [PDF] Reaching All Australiansa - Imgix
    Victor Chang Cardiac Research Institute. Page 10. Expansion. It was a year of expansion for the Victor Chang Cardiac. Research Institute that will ensure its ...
  12. [12]
    Heart Disease Research… | Victor Chang Cardiac Research Institute
    In March 2022, the Victor Chang Cardiac Research Institute and UWA signed an official strategic partnership to significantly boost heart disease research in WA ...
  13. [13]
    Ingham Institute partnership - Victor Chang Cardiac Research Institute
    Sep 28, 2023 · Partnership between the south western Sydney-based Ingham Institute and Victor Chang Cardiac Research Institute to strengthen heart research ...
  14. [14]
    State of the Heart 2025… | Victor Chang Cardiac Research Institute
    Jun 5, 2025 · A key highlight was the announcement of our new collaboration with the Harry Perkins Institute ... © 2025 Victor Chang Cardiac Research Institute.
  15. [15]
    2023 NHMRC Ideas Grant… | Victor Chang Cardiac Research Institute
    Dec 15, 2023 · The Institute's scientists have been successful in the latest round of NHMRC Ideas Grant funding. ... Victor Chang Cardiac Research Institute ...
  16. [16]
    Institute's Researchers Awarded Four NHMRC Ideas Grants
    Dec 18, 2024 · NHMRC CEO Professor Steve Wesselingh says: “NHMRC's Ideas Grant ... Victor Chang Cardiac Research Institute acknowledges Traditional ...
  17. [17]
    2024 Heart Foundation Funding Grants
    Oct 29, 2024 · 2024 Heart Foundation Funding Grants. Institute receives Heart ... Victor Chang Cardiac Research Institute acknowledges Traditional ...
  18. [18]
    Victor Chang Cardiac Research Institute - AAMRI
    Molecular cardiology & biophysics · Developmental & stem cell biology · Cardiac physiology & transplantation · Molecular genetics · Structural & computational ...
  19. [19]
    Australian Heart Disease… - Victor Chang Cardiac Research Institute
    World-class science laboratories researching heart disease · Our Laboratories and Heart Research · Cardiac Electrophysiology · Cardiac Imaging & Therapeutics.Missing: core | Show results with:core
  20. [20]
    Development and Stem Cell… | Victor Chang Cardiac Research ...
    World leading research into congenital heart disease and embryonic heart development. Read more about the research led by prof Richard Harvey.
  21. [21]
    Exploring the role of artificial intelligence (AI) in heart disease
    May 13, 2024 · We caught up with Dr Bart to get her thoughts on how AI is likely to impact cardiology, patient care, and the role of the clinician.Missing: big | Show results with:big
  22. [22]
    Heart Valve Disease and Artificial Intelligence Laboratory
    The Heart Valve Disease and Artificial Intelligence Laboratory focuses on Aortic Stenosis, the most common valvular heart condition in Australia.Missing: big data
  23. [23]
    Victor Chang cardiac research institute | European Heart Journal
    Sep 7, 2016 · The Victor Chang Cardiac Research Institute was established on Valentine's Day 1994, to honour the legacy of Australia's legendary heart ...
  24. [24]
    Spontaneous Coronary Artery Dissection (SCAD)
    Aug 28, 2025 · The Victor Chang Cardiac Research Institute is leading Australia's first research program into Spontaneous Coronary Artery Dissection (SCAD).
  25. [25]
    Victor Chang Cardiac Research Institute SCAD Study Update 2024 ...
    Apr 30, 2025 · Spontaneous coronary artery dissection and a family history of aortic dissection: a genetic association study. JAmer HeartAssoc2025 Apr 15;14(8): ...
  26. [26]
    Elite Rowers at Far Higher Risk of Heart Rhythm Disorder
    Jun 26, 2025 · 26 June 2025. A new study involving 121 former elite rowers from Australia has revealed one in five develops atrial fibrillation (AFib).
  27. [27]
    NOTCH1 - CHDgene
    Disease info · Ventricular septal defect · Bicuspid aortic valve · Aortic stenosis · Coarctation of the aorta · Tetralogy of fallot · Hypoplastic left heart syndrome.
  28. [28]
    Understanding why some families are prone to 'big hearts'
    Understanding why some families are prone to 'big hearts'. The Institute's research into the causes and potential treatments for hypertrophic cardiomyopathy ( ...
  29. [29]
    Environmental Risk Factors Are Associated With the Natural History ...
    May 2, 2025 · Dilated cardiomyopathy (DCM) is an important heart muscle disease associated with significant morbidity and mortality from heart failure (HF), ...
  30. [30]
    Research Grant Recipients 2025 - Heart Foundation
    Oct 22, 2025 · , Victor Chang Cardiac Research Institute Limited, 2025 Future Leader Fellowship - Level 3, Decoding Menopause-Driven Aortic Aneurysms ...
  31. [31]
    Victor Chang Cardiac Research Institute - University Profile
    The total number of all publications by leading scholars in Victor Chang Cardiac Research Institute is 3,295 with a mean value for publications per scientist of ...Missing: journals | Show results with:journals
  32. [32]
    2025 ARC Discovery Project Funding Success
    Nov 28, 2024 · The Institute's scientists have been awarded more than $1 million to further our understanding of biological energy production and examine the ...
  33. [33]
    $$28 million from NHMRC to advance medical research
    Feb 24, 2025 · Professor Jamie Vandenberg from the Victor Chang Cardiac Research Institute and UNSW Medicine & Health received $2,814,025 for Optimising ...
  34. [34]
    Grant Wins & Heart… | Victor Chang Cardiac Research Institute
    “By understanding how menopause affects the heart and blood vessels, we can ultimately save more lives and close the gender gap in heart disease ...
  35. [35]
    Methods, kits and devices for promoting cardiac regeneration
    Application filed by Victor Chang Cardiac Research Institute Ltd, Yeda Research and Development Co Ltd ... Cardiac stem cell therapy and the promise of heart ...
  36. [36]
    Artificial Hearts | Victor Chang Cardiac Research Institute
    How has the Victor Chang Cardiac Research Institute been involved in artificial heart technology? Prof Chris Hayward and Dr Sam Emmanuel with a BiVACOR ...Missing: website history
  37. [37]
    St Vincent's Makes History with Australia's First Total Artificial Heart ...
    Mar 12, 2025 · St Vincent's has once again cemented its reputation as a global leader in cardiac care by successfully implanting Australia's first BiVACOR Total Artificial ...
  38. [38]
    https://research.com/university/victor-chang-cardiac-research-institute
  39. [39]
    Contact us | Victor Chang Cardiac Research Institute
    General Enquiries: info@victorchang.edu.au Address Victor Chang Cardiac Research Institute Lowy Packer Building 405 Liverpool St, Darlinghurst NSW 2010 ...
  40. [40]
    https://www.unsw.edu.au/newsroom/news/2025/02/28-million-from-nhmrc-to-advance-medical-research
  41. [41]
    Innovation Centre | Victor Chang Cardiac Research Institute
    The Innovation Centre is dedicated to facilitating and expediting research outcomes across all aspects of human health including cardiovascular disease.
  42. [42]
    Lowy Packer Building… | Victor Chang Cardiac Research Institute
    Mar 2, 2021 · Moving towards a more sustainable future at the Victor Chang Cardiac Research Institute · The building's gas and electricity usage has reduced by ...Missing: renovations | Show results with:renovations
  43. [43]
    Victor Chang Cardiac Research Institute - Developmental Biology ...
    Apr 26, 2016 · Plans began in 2002 for a new building to house the growing institute. The inclusion of a facility to breed and conduct research with rodent ...Missing: history | Show results with:history
  44. [44]
    New Heart, Exercise and… | Victor Chang Cardiac Research Institute
    Sep 13, 2023 · New Heart, Exercise and Research Trials lab, powered by partnership with SVI ... Clinician-researcher Associate Professor André La Gerche has been ...
  45. [45]
    Heart Disease Research Victoria
    Victor Chang Cardiac Research Institute has expanded its heart research footprint with a new world class laboratory in Victoria.
  46. [46]
    Heart attack breakthrough - Victor Chang Cardiac Research Institute
    World first research, led by the Victor Chang Cardiac Research Institute, has shown it may be possible to both identify those at risk of a heart attack and ...
  47. [47]
    https://svship.org.au/about-us/
  48. [48]
    Perkins partners with Victor Chang Cardiac Research Institute for ...
    May 30, 2025 · Perkins partners with Victor Chang Cardiac Research Institute for better heart outcomes ... © 2025 Harry Perkins Institute of Medical Research.
  49. [49]
    Heart Disease Research South Western Sydney
    Victor Chang Cardiac Research Institute has expanded its heart research footprint with a new partnership in South Western Sydney ... 27 Sep 2023. Read more.
  50. [50]
    Affiliate medical research institutes | Medicine & Health
    The Victor Chang Cardiac Research Institute is Australia's home of heart research, and we're dedicated to finding cures for cardiovascular disease.Missing: Mayo | Show results with:Mayo
  51. [51]
    Victor Chang Cardiac Research Institute (VCCRI) - Nature
    The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Victor Chang Cardiac Research ...
  52. [52]
    Our Organisation Structure - Victor Chang Cardiac Research Institute
    View the organisational structure of the executive team at the Victor Chang Cardiac Research Institute.
  53. [53]
    Grounds to take over chair at Victor Chang Research Institute - AFR
    Dec 16, 2013 · Star investment banker Matthew Grounds will be appointed the new chairman of the Victor Chang Cardiac Research Institute, replacing ...
  54. [54]
    Our Board | Victor Chang Cardiac Research Institute
    Board of Directors ; Mr Matthew Grounds AM. Chairman Co-Executive Chair, Barrenjoey Capital Partners ; Mr David Craig. Deputy Chairman Former CFO, Commonwealth ...
  55. [55]
    New Board Member: Dr Philip Lowe
    Jun 30, 2025 · Former Reserve Bank Governor Dr Philip Lowe Joins the Board of the Victor Chang Cardiac Research Institute. 30 June 2025. The Victor Chang ...Missing: list | Show results with:list
  56. [56]
    We're pleased to announce that Ms Christine Fleer is joining our ...
    Jul 4, 2024 · We're pleased to announce that Ms Christine Fleer is joining our Board of Directors. Ms Fleer is a partner of law firm Arnold Bloch ...
  57. [57]
    Victor Chang Cardiac Research Institute - Wikipedia
    The Victor Chang Cardiac Research Institute (VCCRI) is an Australian non-profit medical research facility that is dedicated to finding cures for cardiovascular ...
  58. [58]
    [PDF] Delivering our vision through 2030 - Imgix
    Founded in 1994, the Victor Chang Cardiac Research Institute was established in honour of the legendary heart transplant surgeon Dr Victor Chang. Now ...
  59. [59]
    Philanthropy | Victor Chang Cardiac Research Institute
    When you make a gift to the Victor Chang Cardiac Research Institute, your funds help support scientific research specifically geared towards combatting the many ...Missing: strategic plan
  60. [60]
    New Executive Director… | Victor Chang Cardiac Research Institute
    Apr 3, 2020 · Professor Jason Kovacic has been named as the new Executive Director of the Victor Chang Cardiac Research Institute (VCCRI), commencing in March 2020.
  61. [61]
    Professor Sally Dunwoodie's Research on Niacin & Birth Defects
    Nov 12, 2017 · Prof. Sally Dunwoodie, of the Victor Chang Cardiac Research Institute, led a team in discovering that low levels of nicotinamide adenine ...
  62. [62]
    Professor Jamie Vandenberg | Victor Chang Cardiac Research ...
    Professor Vandenberg is recognised internationally as an expert in cardiac electrophysiology, particularly for his research on cardiac ion channels.
  63. [63]
    Victor Chang Cardiac Research Institute | Cardiac Electrophysiology…
    Prof Jamie Vandenberg, Co-Deputy Director and Head of Cardiac Electrophysiology Laboratory. “Our mission? To reduce sudden cardiac death in the young”<|control11|><|separator|>
  64. [64]
    Victor Chang Cardiac Research Institute's Post - LinkedIn
    Oct 26, 2025 · We are pleased to announce the appointment of Suzie Blinman as Deputy CEO of the Victor Chang Cardiac Research Institute.
  65. [65]
    Victor Chang Cardiac Research Institute | Prof Nigel Turner
    ### Summary of Prof Nigel Turner
  66. [66]
    Finding New Pathways and Treatments to Beat Pancreatic Cancer
    Nov 21, 2024 · Prof Nigel Turner is studying cellular metabolism to help develop new treatments for pancreatic cancer - one of the most lethal cancers.
  67. [67]
    Victor Chang Cardiac Research Institute | Professor Diane Fatkin
    ### Summary of Professor Diane Fatkin
  68. [68]
    https://www.victorchang.edu.au/about-us/our-scientists/prof-jamie-vandenberg
  69. [69]
    Titin-related familial dilated cardiomyopathy: factors associated with ...
    Aug 11, 2025 · Disease onset in TTNtv-associated familial DCM is dependent on individual patient context and is potentially modifiable by risk factor ...
  70. [70]
    Dilated Cardiomyopathy Breakthrough
    Aug 12, 2025 · Dilated Cardiomyopathy Breakthrough. Breakthrough could help prevent or delay heart condition that can cause heart failure and sudden cardiac ...Missing: 2024 | Show results with:2024
  71. [71]
    Dr Eleni Giannoulatou | Victor Chang Cardiac Research Institute
    A/Prof Giannoulatou's research focuses on identifying the underlying genetic determinants of cardiovascular disease.
  72. [72]
    Genome-wide association meta-analysis of spontaneous coronary ...
    May 29, 2023 · Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia. Eleni Giannoulatou, Siiri E. Iismaa, Ingrid Tarr, David W. M. ...
  73. [73]
    2024 new Young Appeals Committee appointments
    Nov 11, 2024 · The Institute announces Ninette Khouri, Jack Freeman, and Rebecca LeBherz join its Young Appeals Committee (YAC).
  74. [74]
    How billionaires, surgeons and royals built the Victor Chang institute
    Nov 16, 2019 · At the centre of the institute Graham created was the spirit of the late Dr Victor Chang, a cardiac surgeon respected and adored by his patients ...